Focus on Alternative and Complementary Therapies
www.pharmpress.com/fact
Focus Alternat Complement Ther©2005 Pharmaceutical Press
Focus Altern Complement Ther 2006; 11: 27–8
This study assessed the prevalence and determinants of traditional Chinese medicine (TCM)/CAM use in newly diagnosed Chinese cancer patients.
A consecutive sample of Chinese cancer patients treated at the British Columbia Cancer Agency was surveyed at admission, using a 15-item questionnaire. Items included TCM/CAM use, socio-demographics and medical and cultural factors.
Of the 130 respondents, 55% completed the survey in Chinese and 91% were first generation immigrants. The average age was 60. Patients had a mean disease duration of 2 months and 70% had already received at least one conventional treatment. Overall, TCM/CAM was used by 45% of respondents. However, for those defined as less acculturated (such as being born outside Canada) the prevalence was higher (54%). Herbal remedies, vitamins/minerals and prayer were the most commonly used therapies. In the bivariate analysis, factors associated with TCM/CAM use were prior TCM/CAM use (P<0.001), female sex (P=0.021), lower income (P=0.033), having received conventional treatment(s) (P=0.010), completing the survey in Chinese (P=0.037), reporting that they most frequently use a non-official language at home (P=0.032) and being less acculturated (P=0.025). Multivariate analysis showed that prior TCM/CAM use (P<0.001), lower income (P=0.031) and being less acculturated (P=0.019) were associated with TCM/CAM use.
Prevalence of use was found to vary as a function of the degree of acculturation to Canada. Healthcare practitioners would be well advised to discuss TCM/CAM use with their patients, especially those who are less acculturated to Western society, since they are the most likely users of TCM/CAM.
This study was funded by a grant from the Canadian Institutes for Health Research-sponsored Palliative Care in a Cross-cultural Context New Emerging Team and the Cancer Complementary & Alternative Medicine Research Team, funded by the National Cancer Institute of Canada with funds from the Canadian Cancer Society.